Trial of solanezumab for mild dementia due to Alzheimer's disease

New England Journal of Medicine

Volumn 378, Issue 4, 2018, Pages 321-330

  Honig, Lawrence S ^a   Vellas, Bruno ^b   Woodward, Michael ^c,d   Boada, Mercè ^e   Bullock, Roger ^f   Borrie, Michael ^g   Hager, Klaus ^h   Andreasen, Niels ⁱ   Scarpini, Elio ^j   Liu Seifert, Hong ^k   Case, Michael ^k   Dean, Robert A ^l   Hake, Ann ^k   Sundell, Karen ^k   Hoffmann, Vicki Poole ^k   Carlson, Christopher ^k   Khanna, Rashna ^k   Mintun, Mark ^k,m   DeMattos, Ronald ^k   Selzler, Katherine J ^k   Siemers, Eric ^k   more..

^a New York Presbyterian Columbia University Medical Center   (United States)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c AUSTIN HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Research Center and Memory Clinic   (Spain)

^f VICTORIA HOSPITAL   (United Kingdom)

^g WESTERN UNIVERSITY   (Canada)

^h Clinic for Medicine of the Elderly   (Germany)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF MILAN   (Italy)

^k ELI LILLY   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m AVID RADIOPHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; SOLANEZUMAB; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; AMYLOID BETA PROTEIN[1-42] CEREBROSPINAL FLUID LEVEL; ARTICLE; BRAIN EDEMA; CLINICAL OUTCOME; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; DYSURIA; EFFUSION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SPONDYLOSIS; TREATMENT DURATION; VITAMIN D DEFICIENCY; AMYLOID PLAQUE; CEREBROSPINAL FLUID; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEMENTIA ASSESSMENT; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; TREATMENT FAILURE; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MENTAL STATUS AND DEMENTIA TESTS; MIDDLE AGED; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; TREATMENT FAILURE;

EID: 85041410704     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1705971     Document Type: Article

References (27)

1. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-98.
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
4. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3: 1.
5. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mildto- moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-21.
6. Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 2016; 12: 110-20.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
9. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: Suppl 2: S13-S21.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
11. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: Suppl 2: S33-S39.
12. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004; 52: 1070-6.
13. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992; 31: 242-9.
14. O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's Research Consortium study. Arch Neurol 2008; 65: 1091-5.
15. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37: 323-9.
16. Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for clinical trials: the Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis 2015; 2: 227-41.
17. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-70.
18. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-33.
19. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
20. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016; 537: 50-6.
21. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-9.
22. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-5.
23. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-7.
24. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45-51.
25. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016; 8: 595-608.
26. Harrison JR, Owen MJ. Alzheimer's disease: the amyloid hypothesis on trial. Br J Psychiatry 2016; 208: 1-3.
27. Hardy J, De Strooper B. Alzheimer's disease: where next for anti-amyloid therapies? Brain 2017; 140: 853-5.